This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2

Sponsored by Aridis Pharmaceuticals, Inc.

About this trial

Last updated 2 years ago

Study ID

AR-320-003

Status

Recruiting

Type

Interventional

Phase

Phase 3

Placebo

Yes

Accepting

18-75 Years
12 to 65 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended a year ago

What is this trial about?

Clinical trial looking at safety and efficacy of suvratoxumab in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients

What are the participation requirements?

Yes

Inclusion Criteria

1. Colonized with Staphylococcus aureus;

2. Expected to require prolonged intubation and mechanical ventilation, without any evidence of active pneumonia.

No

Exclusion Criteria

1. Staphylococcal disease at randomisation;

2. Lung injury score consistent with pneumonia;

3. Chronic tracheostomy patients;

4. The study subject is moribund

5. Receipt of anti- S. aureus systemic antibiotics

6. Active pulmonary disease

Locations

Location

Status

Recruiting